Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Antinuclear antibody (ANA) negativity appears to increase the likelihood of developing malignancy in patients with adult-onset dermatomyositis (DM) within 3 years of diagnosis of their DM, according to a recent study.
New drug applications approved by US FDA as of 16 - 30 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
The use of 5% fluorouracil cream was most effective among a panel of four treatments commonly used for treating multiple actinic keratosis (AK) lesions on the head, according to a recent study.
Women who adopt healthy diets appear to have less severe facial wrinkles, according to a new Dutch study.
Treatment with 300-mg secukinumab confers benefits among patients with palmoplantar pustular psoriasis (PPP) in terms of Palmoplantar Psoriasis Area and Severity Index (PPPASI75) responses over 52 weeks and improved quality of life (QOL), results of the 2PRECISE study have shown.
Psoriasis appears to be a risk factor for mortality from all causes in a dose-response manner with disease severity and from several specific causes, suggest the results of a systematic review and meta-analysis.
An online, collaborative connected-health model is as effective as in-person care at improving quality of life (QOL) among patients with psoriasis, a recent study has shown.
Special Reports
Sunscreen products commonly contain only filters against ultraviolet (UV) radiation. At a recentdinner symposium organized by Eucerin, Dr Rungsima Wanitphakdeedecha discussed whythis is insufficient and what is required for effective protection against the damaging effects ofsunlight on the skin
In conjunction with the launch of QV Intensive with Ceramides (Ego Pharm), the important role of ceramides in themanagement of atopic dermatitis (AD) was highlighted by two distinguished speakers, Dr Agnes Heng of KPJ and Pantai Hospital Ipoh, as well as Dr Fabrizio Spada of Ego Pharmaceuticals, Australia.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
A wound is a disruption of the normal structure and function of the epidermis. Wounds maybe caused by acute traumatic injury to the skin, or other aetiologies that cause initially intact skin to break down. Recently, Dato’ Dr Ho Teik Kok shared his insights into the importance of micronutrients for wound recovery, stressing on the importance of treating the underlying diseases that may impede wound healing.
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that
can present in many different forms. However, it is principally
characterized by dry skin, intense itching, and the presence of
inflammatory skin lesions. [J Eur Acad Dermatol Venereol
2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet
2016;387:1109-1122]
At the 42nd Annual Dermatology Conference 2017 held recently in Kuala Lumpur, Professor Michael J. Cork spoke on the interaction between genetic and environmental factors as a primary event in the development of atopic dermatitis (AD) and highlighted the role of topical calcineurin inhibitors (TCIs) in the management of AD.
Conference Reports
Patients with moderate-to-severe atopic dermatitis (AD) were more likely to have clinically meaningful responses when treated with dupilumab at doses of 300 mg either weekly or every 2 weeks compared with those on placebo, according to a post hoc analysis of the phase III SOLO 1 and SOLO 2* trials presented as a poster at AAD 2019.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.
The novel Janus kinase (JAK) inhibitor delgocitinib exhibited favourable efficacy and safety for moderate-to-severe atopic dermatitis (AD), according to a phase III study presented at AAD 2019.
The benefits of the fully human monoclonal antibody secukinumab at doses of either 150 or 300 mg weekly in patients with active psoriatic arthritis are sustained even after 4 years, according to updated results of the FUTURE 2* study presented at the Inflammatory Skin Disease Summit (ISDS 2018).
Treatment with risankizumab, an interleukin-23 inhibitor, significantly improves skin appearance in patients with moderate-to-severe plaque psoriasis, according to the IMMvent* study presented at the Inflammatory Skin Disease Summit (ISDS).
